[Reporter' View] Results from J.P. Morgan Conference

should be shared

The Annual J.P.

 

Morgan Healthcare Conference (hereafter J.P.

 

Morgan Conference) has ended.

 

It is the largest funding event in the pharmaceutical and biotech industry and is held in January every year.

 

Many Korean companies have also participated in the event, to the extent that many key R&D people in the Korean pharmaceutical and biotech industry were said to be not present in Korea.

 

According to the J.P.

 

Morgan Conference report, almost 30,000 one-on-one business meetings requested at this year's event were held, where 12,000 agreements have been met.

 

The total market capitalization of 531 companies at the official presentation sessions is US$ 9.6 trillion.

 

Consequently, the J.P.

 

Morgan Conference presents an opportunity for Korean pharmaceutical and biotech companies.

 

According to the J.P.

 

Morgan Conference report, almost 30,000 one-on-one business meetings requested at this year's event were held, where 12,000 agreements have been met.

 

The total market capitalization of 531 companies at the official presentation sessions is US$ 9.6 trillion.

 

Consequently, the J.P.

 

Morgan Conference presents an opportunity for Korean pharmaceutical and biotech companies.

 

Companies referred to as conglomerates in the pharmaceutical industry have unveiled their specific accomplishments.

 

For instance, Yuhan presented its latest data on the new lung cancer drug, Leclaza, through its partner, Johnson & Johnson (J&J).

 

Joaguin Duato, CEO of J&J, said, "A combination therapy of Leclaza and Rybrevant demonstrated results of extending three-year life-expectancy of lung cancer patients over a year.

 

It is a difference that may bring changes to the treatment paradigm." UK-based AstraZeneca's Tagrisso (osimertinib), the standard therapy used in patients with EGFR-mutated non-small cell lung cancer (NSCLC) has the median overall survival (mOS) of approximately 3 years.

 

The combination therapy of Leclaza and Rybrevant is expected to have a mOS of over 4 years.

 

J&J projected the yearly sales goal for Leclaza+Rybrevant to be over KRW 7 trillion.

 

Samsung Biologics announced that it will begin the antibody-drug conjugate (ADC) service in the first quarter of this year.

 

The company aimed to provide top-level Contract Development and Manufacturing Organization (CDMO) services in the ADC field.

 

Moreover, the company announced the building of Plant 6 facility this year.

 

Other companies, including Celltrion, Lotte Biologics, Hugel, and SK Biopharmaceuticals, presented their R&D vision.

 

These companies have shared their success at the J.P.

 

Morgan conference.

 

In contrast, some companies showed a different stance before and after the conference.

 

It is difficult to estimate, but based on yearly trends, more than half of the companies that promoted before the conference did not issue additional press reports afterwards.

 

Despite using promotional keywords, such as promoting technology transports, disclosing growth strategies, conducting big pharma meetings, and establishing facilities, these companies failed to release feedback after attending the J.P.

 

Morgan Conference.

 

The J.P.

 

Morgan Conference has ended.

 

Companies must release their accomplishments following the conference if they genuinely wish to be acknowledged for their company values.

 

Rather than issuing promotional press releases beforehand, they should share objective results afterward.

 

If one issues a promotional subject, providing feedback is essential.

 

Additionally, companies must announce their accomplishments.

 

Disclosable materials are limitless, depending on how companies view them.

 

This week is the best time for companies to showcase their successes at the J.P.

 

Morgan Conference.